Mucormycosis, Past and Present: A Comprehensive Review
Future Microbiology · 2023-02 · 18 (3) · 217-234
DOI: 10.2217/fmb-2022-0141 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Future Microbiology, online erschienen am 27.03.2023. Verfasst von Ishita Gupta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Ram Lal Anand College, University of Delhi, Benito Juarez Road, New Delhi, 110021, India. Hauptthemen laut MEDLINE: Mucormycosis, COVID-19, Neutropenia, Opportunistic Infections. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 94 Literaturangaben.
Abstract (Originalsprache)
Mucormycosis is an emerging opportunistic angioinvasive fungal infection. Predisposing factors such as diabetes, neutropenia, long-term corticosteroid therapy, solid organ transplantation and immunosuppression contribute to its occurrence. This disease was not of significant concern prior to the COVID-19 pandemic, but gained prominence due to infections in COVID-19 patients. Mucormycosis needs special attention and coordinated efforts of the scientific community and medical professionals to reduce morbidity and mortality. Here we present an overview of the epidemiology and prevalence of mucormycosis in the pre- and post-COVID-19 eras, the factors that contributed to the abrupt increase in COVID-19-associated mucormycosis (CAM), the actions taken by the regulatory agencies (including Code Mucor and CAM registry), the existing diagnostic tools and CAM management strategies. The devastating effects of the COVID-19 pandemic have been further enhanced by various secondary illnesses, particularly opportunistic fungal infections such as mucormycosis. Mucormycosis or ‘black fungus’ primarily affects people with weakened immunity, those with medical conditions such as diabetes or cancer and those who use medications that reduce the body's capacity to resist infections and disease. The infection starts in the sinuses or the lungs after breathing in spores of the black fungus from the air. In just 2 months between 5 May and 12 July 2021, this uncommon but fatal fungal illness was responsible for 41,512 cases and 3554 fatalities in India alone. The government of India declared a mucormycosis epidemic in May 2021. The majority of such cases occurred during active SARS-CoV-2 outbreaks in India in 2021. Black fungus took over while the host defenses were compromised and the globe was preoccupied tackling the COVID-19 pandemic. Steroids prescribed in amounts and time spans that far exceeded WHO recommendations to manage severe COVID-19 cases, potentially weakened patients' immune systems, and raised blood sugar levels making them vulnerable to fungal invasion. Early diagnosis and treatment are the keys to a patient's survival. Simple means such as maintaining hygienic conditions, avoiding contact with an infected person, judiciously using steroid medications and antibiotics and properly managing high blood sugar can help protect an individual from black-fungus infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology, Ram Lal Anand College, University of Delhi, Benito Juarez Road, New Delhi, 110021, India.
- Section of Microbiology, Central Ayurveda Research Institute, Jhansi, Uttar Pradesh, 284003, India.
ORCID-Profile: Ishita Gupta, Pritika Baranwal, Gagandeep Singh, Vandana Gupta
Zitieren
APA
Gupta, I., Baranwal, P., Singh, G., & Gupta, V. (2023). Mucormycosis, Past and Present: A Comprehensive Review. Future Microbiology, 18(3), 217-234. https://doi.org/10.2217/fmb-2022-0141
Vancouver
Gupta I, Baranwal P, Singh G, Gupta V. Mucormycosis, Past and Present: A Comprehensive Review. Future Microbiology. 2023;18(3):217-234. doi:10.2217/fmb-2022-0141
BibTeX
@article{Gupta2023,
author = {Gupta, Ishita and Baranwal, Pritika and Singh, Gagandeep and Gupta, Vandana},
title = {Mucormycosis, Past and Present: A Comprehensive Review},
journal = {Future Microbiology},
year = {2023},
volume = {18},
number = {3},
pages = {217--234},
doi = {10.2217/fmb-2022-0141}
}
EUVIMED